JP2010502585A - ６８Ｇａ標識ペプチド系放射性医薬品 - Google Patents

６８Ｇａ標識ペプチド系放射性医薬品 Download PDF

Info

Publication number
JP2010502585A
JP2010502585A JP2009526190A JP2009526190A JP2010502585A JP 2010502585 A JP2010502585 A JP 2010502585A JP 2009526190 A JP2009526190 A JP 2009526190A JP 2009526190 A JP2009526190 A JP 2009526190A JP 2010502585 A JP2010502585 A JP 2010502585A
Authority
JP
Japan
Prior art keywords
compound
compound according
amino acid
receptor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009526190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502585A5 (enExample
Inventor
ラングストロム，ベント
ヴェリクヤン，イリーナ
ベルグストローム，マット
リンデ，オルヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2010502585A publication Critical patent/JP2010502585A/ja
Publication of JP2010502585A5 publication Critical patent/JP2010502585A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
JP2009526190A 2006-08-28 2007-08-28 ６８Ｇａ標識ペプチド系放射性医薬品 Pending JP2010502585A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82368206P 2006-08-28 2006-08-28
PCT/IB2007/002479 WO2008026040A2 (en) 2006-08-28 2007-08-28 68ga-labeled peptide-based radiopharmaceuticals

Publications (2)

Publication Number Publication Date
JP2010502585A true JP2010502585A (ja) 2010-01-28
JP2010502585A5 JP2010502585A5 (enExample) 2011-09-15

Family

ID=38961954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009526190A Pending JP2010502585A (ja) 2006-08-28 2007-08-28 ６８Ｇａ標識ペプチド系放射性医薬品

Country Status (5)

Country Link
US (1) US20100233082A1 (enExample)
EP (1) EP2056886A2 (enExample)
JP (1) JP2010502585A (enExample)
CN (1) CN101528270A (enExample)
WO (1) WO2008026040A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524423A (ja) * 2011-08-12 2014-09-22 アドヴァンスド アッチェレラター アプリケーションズ ソシエテ アノニム ６８ｇａ錯体の調製方法
JP2018518523A (ja) * 2015-06-23 2018-07-12 ガイズ アンド セント トーマスズ ホスピタル エヌエイチエス ファンデーション トラストＧｕｙ’Ｓ Ａｎｄ Ｓｔ Ｔｈｏｍａｓ’ Ｈｏｓｐｉｔａｌ Ｎｈｓ Ｆｏｕｎｄａｔｉｏｎ Ｔｒｕｓｔ 関節炎を画像化する方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722858C (en) * 2008-04-30 2017-08-29 Siemens Medical Solutions Usa, Inc. Substrate based pet imaging agents
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
WO2011021390A1 (ja) * 2009-08-20 2011-02-24 富士フイルムＲｉファーマ株式会社 ビスホスホン酸誘導体及びその放射性金属核種標識体
US9884131B2 (en) 2012-12-03 2018-02-06 Curasight Aps Positron emitting radionuclide labeled peptides for human uPAR PET imaging
JP2020506921A (ja) * 2017-01-30 2020-03-05 ヴェクト−オールＶｅｃｔ−Ｈｏｒｕｓ がんイメージング及びがん放射線治療のための組成物及び方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531835A (ja) * 2000-04-12 2003-10-28 アメルシャム ヘルス アクスイェ セルスカプ ペプチドベースの化合物
JP2004509975A (ja) * 2000-09-26 2004-04-02 アメルシャム　ヘルス　アクスイェ　セルスカプ ペプチド系化合物
WO2004089425A1 (en) * 2003-04-11 2004-10-21 Ge Healthcare Limited Microwave method for preparing radiolabelled gallium complexes
JP2005507376A (ja) * 2001-07-10 2005-03-17 アメルシャム ヘルス アクスイェ セルスカプ ペプチドベースの化合物
WO2006054904A2 (en) * 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
WO2006067376A2 (en) * 2004-12-22 2006-06-29 Hammersmith Imanet Limited Radiolabelled conjugates of rgd-containing peptides and methods for their preparation via click-chemistry

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531835A (ja) * 2000-04-12 2003-10-28 アメルシャム ヘルス アクスイェ セルスカプ ペプチドベースの化合物
JP2004509975A (ja) * 2000-09-26 2004-04-02 アメルシャム　ヘルス　アクスイェ　セルスカプ ペプチド系化合物
JP2005507376A (ja) * 2001-07-10 2005-03-17 アメルシャム ヘルス アクスイェ セルスカプ ペプチドベースの化合物
WO2004089425A1 (en) * 2003-04-11 2004-10-21 Ge Healthcare Limited Microwave method for preparing radiolabelled gallium complexes
WO2006054904A2 (en) * 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
WO2006067376A2 (en) * 2004-12-22 2006-06-29 Hammersmith Imanet Limited Radiolabelled conjugates of rgd-containing peptides and methods for their preparation via click-chemistry

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J.NUCL.MED.,VOL.46,NO.11(2005)P.1881-1888, JPN6012043463, ISSN: 0002308174 *
NUCL.MED.BIOL.,VOL.29,NO.2(2002)P.147-157, JPN6012043464, ISSN: 0002308175 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524423A (ja) * 2011-08-12 2014-09-22 アドヴァンスド アッチェレラター アプリケーションズ ソシエテ アノニム ６８ｇａ錯体の調製方法
JP2018518523A (ja) * 2015-06-23 2018-07-12 ガイズ アンド セント トーマスズ ホスピタル エヌエイチエス ファンデーション トラストＧｕｙ’Ｓ Ａｎｄ Ｓｔ Ｔｈｏｍａｓ’ Ｈｏｓｐｉｔａｌ Ｎｈｓ Ｆｏｕｎｄａｔｉｏｎ Ｔｒｕｓｔ 関節炎を画像化する方法

Also Published As

Publication number Publication date
WO2008026040A2 (en) 2008-03-06
EP2056886A2 (en) 2009-05-13
WO2008026040A3 (en) 2008-05-08
US20100233082A1 (en) 2010-09-16
CN101528270A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
US12409240B2 (en) Positron emitting radionuclide labeled peptides for human uPAR PET imaging
EP3223866B1 (en) Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain
IL275317B (en) A complex containing a compound against psma attached to a radioactive nucleus of lead or thorium
NO333066B1 (no) Peptidbaserte forbindelser, farmasoytisk sammensetning omfattende en slik forbindelse, anvendelse av en slik forbindelse samt fremgangsmate for a danne bilder av et menneske eller en annen dyrekropp.
JP2010502585A (ja) ６８Ｇａ標識ペプチド系放射性医薬品
US20250170243A1 (en) Stable formulations for radionuclide complexes
US20110117012A1 (en) Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors
AU2020367415A1 (en) RI-labeled humanized antibody
Tolmachev et al. Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules
JP7744240B2 (ja) キレート化ａａｚｔａコンジュゲートおよびその錯体
WO2024064969A2 (en) High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
Liu et al. Radiolabeled integrin αvβ3 antagonists as radiopharmaceuticals for tumor radiotherapy
Käkelä et al. Adventures in radiosynthesis of clinical grade [68 Ga] Ga-DOTA-Siglec-9
US20250009911A1 (en) DOTA-HYNIC-iPSMA AS A THERAPEUTIC RADIOPHARMACEUTICAL TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN
Mirković et al. Design and evaluation of Cu (II)-HMPAO complex as a representative model for assessing the potential of 64Cu radiopharmaceutical
Arev et al. Development of ready to use kit formulation for trastuzumab radioimmunoconjugates and identification of radiochemical purity as the first step in quality control of the final product
KR20230174238A (ko) 방사성 항종양제
KR20230174243A (ko) β선을 방출하는 핵종으로 표지된 인간화 항체
Schweinsberg Novel 99mTc-labeled bombesin analogues with improved pharmacokinetics for targeting of gastrin-releasing-peptide receptor-positive tumors
JP2002293796A (ja) 標識ペプチドによるシトクロムｃの造影・検出試薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111005

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20111005

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20111005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130423